BeyondSpring's Subsidiary SEED Therapeutics Has Received FDA Orphan Drug Designation For ST-01156 For Treatment Of Neuroblastoma

Benzinga Newsdesk www.benzinga.com Neutral 92.3%

Neg 0% Neu 92.3% Pos 0%

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1149926

Comments

No comments yet. Be the first!